Download PDF
Aktuelle Dermatologie 2006; 32(7): 303-308
DOI: 10.1055/s-2006-944580
Eine Klinik im Blickpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Die Rolle der Hormone für die Hautalterung - Aktuelle Aspekte

The Role of Hormones in Skin Ageing - Current AspectsE.  Makrantonaki1, 2 , C.  C.  Zouboulis1, 2
  • 1Hautklinik und Immunologisches Zentrum, Städtisches Klinikum Dessau (Chefarzt: Prof. Dr. C. C. Zouboulis)
  • 2Labor für Biogerontologie, Dermato-Pharmakologie und Dermato-Endokrinologie, Institut für Klinische Pharmakologie und Toxikologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (Leiter: Prof. Dr. C. C. Zouboulis)
Herrn Prof. Dr. Prof. Dr. h. c. Constantin E. Orfanos zum 70. Geburtstag gewidmet.
Further Information

Publication History

Publication Date:
17 July 2006 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die intrinsische Hautalterung spiegelt Abbauprozesse wider, die auch in anderen Körperorganen stattfinden. Hormone sind maßgeblich am Prozess der intrinsischen Alterung beteiligt, der mit einer verminderten Sekretion hypophysärer, adrenaler und gonadaler Hormone einhergeht. Man verbringt aktuell ein Drittel des Lebens (Frauen - Menopause) bzw. mindestens 20 Jahre (Männer - PADAM) unter Östrogen- bzw. Androgenmangel. Weitere Hormone, die mit zunehmendem Alter abnehmen sind Melatonin, Wachstumshormon (GH), Dehydroepiandrosteron und Insulin-like-Growth-Factor-l (IGF-I). Bei den Frauen nimmt neben den Östrogenen auch das Progesteron in der Menopause ab. Da Progesteron die Androgene kontrolliert, kommt es mit zunehmendem Alter bei den Frauen zu einem relativen peripheren Hyperandrogenismus. Eine partielle Prävention oder Unterbrechung des intrinsischen Hautalterungsprozesses ist nach der aktuellen Datenlage durch eine Östrogensubstitution in der Menopause realisierbar. Bei der männlichen Seneszenz sind weitere umfangreiche Untersuchungen notwendig, bevor der klinische Einsatz einer hormonellen Substitution empfohlen werden kann. Erste Hinweise sprechen für einen positiven Einfluss der Testosteron-Substitution bei Männern mit sekundärem Hypogonadismus. Allerdings vermehren sich die Daten darüber, dass GH und IGF-I die eigentlich vom Testosteron erwartete Rolle beim alternden Mann übernehmen. IGF-I scheint dabei bei beiden Geschlechtern eine zentrale Rolle zu spielen. Da die Haut nicht nur eine schützende Funktion für den Organismus hat, sondern auch ein aktives peripheres endokrines Organ ist, das sogar wirksame Hormone im Kreislauf freisetzt, könnten lokale Substitutionswege in der Zukunft interessant werden.

Abstract

Intrinsic skin ageing reflects degradation processes, which also take place in other body organs. Hormones are substantially involved in the process of intrinsic ageing, which occurs along with reduced secretion of pituitary, adrenal and gonadal hormones. One third of human life (women - menopause) or at least 20 years (men - PADAM) run under estrogen or androgen deficiency. Further hormones, which are reduced with advancing age are melatonin, growth hormone (GH), dehydroepiandrosterone and insulin-like growth factor I (IGF-I). Besides estrogens, progesterone is also reduced in menopause. Since progesterone controls the androgens, a relative peripheral hyperandrogenism occurs with advancing age. Partial prevention or interruption of the intrinsic skin ageing process can be achieved by hormonal substitution, however this is currently not widely practicable due the current data status. Further extensive studies of the male senescence are required before hormonal substitution can be recommended. First data hint on a positive influence of testosterone substitution among men with secondary hypogonadism. Accumulating data indicate that GH and IGF I overtake the role expected for testosterone in ageing male. IGF-I actually seems to play a central role in the ageing process in both sexes. Since the skin has not only a protective function for the human organism but is also an active peripheral endocrine organ, which even releases active hormones in the circulation, topical hormonal substitution may become an interesting regimen in the future.

Literatur

  • 1 Zouboulis C C. Human skin: an independent peripheral endocrine organ.  Horm Res. 2000;  54 230-242
    CrossrefPubMedGoogle Scholar
  • 2 Ebling F JG. The hormonal control of hair growth. In: Orfanos CE, Happle R (eds) Hair and hair growth. Berlin, Heidelberg, New York; Springer 1990: 267-299
    Google Scholar
  • 3 Fritsch M, Orfanos C E, Zouboulis C C. Sebocytes are the key regulators of androgen homeostasis in human skin.  J Invest Dermatol. 2001;  116 793-800
    CrossrefPubMedGoogle Scholar
  • 4 Suzuki I, Cone C D, Im S, Nordlund J, Abdel-Malek Z A. Binding of melanocortin hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis.  Endocrinology. 1996;  137 1627-1633
    CrossrefPubMedGoogle Scholar
  • 5 Deplewski D, Rosenfield R L. Role of hormones in pilosebaceous unit development.  Endocr Rev. 2000;  21 363-392
    CrossrefPubMedGoogle Scholar
  • 6 Stenn K S, Paus R. Control of hair follicle cycling.  Physiol Rev. 2001;  81 449-494
    PubMedGoogle Scholar
  • 7 Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M. Intracrinology and the skin.  Horm Res. 2000;  54 218-229
    CrossrefPubMedGoogle Scholar
  • 8 Orfanos C E, Adler Y D, Zouboulis C C. The SAHA syndrome.  Horm Res. 2000;  54 251-258
    CrossrefPubMedGoogle Scholar
  • 9 Phillips T J, Demircay Z, Sahu M. Hormonal effects on skin aging.  Clin Geriatr Med. 2001;  17 661-672
    CrossrefPubMedGoogle Scholar
  • 10 Thiboutot D M. Dermatological manifestations of endocrine disorders.  J Clin Endocrinol Metab. 1995;  80 3082-3087
    CrossrefPubMedGoogle Scholar
  • 11 Zouboulis C C. Pathologie der alternden männlichen Haut. In: Schill W-B, Bretzel RG, Weidner W (Hrsg) MännerMedizin in der allgemeinmedizinischen und internistischen Praxis. München; Elsevier Urban & Fischer 2005: 220-225
    Google Scholar
  • 12 Greenspan F S, Gardner D G. Basic and clinical endocrinology, 6th edn. New York; McGraw Hill 2001
    Google Scholar
  • 13 Brincat M P. Hormone replacement therapy and the skin.  Maturitas. 2000;  35 107-117
    CrossrefPubMedGoogle Scholar
  • 14 Morley J E. Androgens and aging.  Maturitas. 2001;  38 61-73
    CrossrefPubMedGoogle Scholar
  • 15 Callens A, Vaillant L, Lecomte P, Berson M, Gall Y, Lorette G. Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques.  Dermatology. 1996;  193 289-294
    CrossrefPubMedGoogle Scholar
  • 16 Rudman D, Feller A G, Nagraj H S, Gergans G A, Lalitha P Y, Goldberg A F, Schlenker R A, Cohn L, Rudman I W, Mattson D E. Effects of human growth hormone in men over 60 years old.  N Engl J Med. 1990;  323 1-6
    CrossrefPubMedGoogle Scholar
  • 17 Raine-Fenning N J, Brincat M P, Muscat-Baron Y. Skin aging and menopause: implications for treatment.  Am J Clin Dermatol. 2003;  4 371-378
    CrossrefPubMedGoogle Scholar
  • 18 Sator P G, Schmidt J B, Rabe T, Zouboulis C C. Skin aging and sex hormones in women - clinical perspectives for intervention by hormone replacement therapy.  Exp Dermatol. 2004;  13 (Suppl 4) 36-40
    CrossrefPubMedGoogle Scholar
  • 19 Dieudonne M N, Pecquery R, Leneveu M C, Giudicelli Y. Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor γ2.  Endocrinology. 2000;  141 649-656
    CrossrefPubMedGoogle Scholar
  • 20 Tavakkol A, Varani J, Elder J T, Zouboulis C C. Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor.  Arch Dermatol Res. 1999;  291 643-651
    CrossrefPubMedGoogle Scholar
  • 21 Ma H, Sprecher H W, Kolattukudy P E. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ- expressing tissue.  J Biol Chem. 1998;  273 30 131-30 138
    PubMedGoogle Scholar
  • 22 Rosenfield R L, Kentsis A, Deplewski D, Ciletti N. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors.  J Invest Dermatol. 1999;  112 226-232
    CrossrefPubMedGoogle Scholar
  • 23 Miller K K. Androgen deficiency in women.  J Clin Endocrinol Metab. 2001;  86 2395-2401
    CrossrefPubMedGoogle Scholar
  • 24 Makrantonaki E, Oeff M K, Fimmel S, Zouboulis C C. Molecular mechanisms of hormone-induced skin aging.  Exp Dermatol. 2003;  12 333
    PubMedGoogle Scholar
  • 25 Chen W, Yang C-C, Sheu H-M, Seltmann H, Zouboulis C C. Expression of peroxisome proliferator- activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes.  J Invest Dermatol. 2003;  121 441-447
    CrossrefPubMedGoogle Scholar
  • 26 Oettel M. Is there a role for estrogens in the maintenance of men’s health?.  Aging Male. 2002;  5 248-257
    PubMedGoogle Scholar
  • 27 Katz M S. Geriatric grand rounds: Eve’s rib, or a revisionist view of osteoporosis in men.  J Gerontol A Biol Sci Med Sci. 2000;  55 M560-M569
    PubMedGoogle Scholar
  • 28 Brossner C, Petritsch K, Fink K, Auprich M, Madersbacher S, Adlercreutz H, Rehak P, Petritsch P. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.  Urology. 2004;  64 707-711
    CrossrefPubMedGoogle Scholar
  • 29 Ponholzer A, Plas E, Schatzl G, Jungwirth A, Madersbacher S,. Austrian Society of Urology . Association of DHEA-S and estradiol serum levels to symptoms of aging men.  Aging Male. 2002;  5 233-238
    PubMedGoogle Scholar
  • 30 Juul A, Skakkebaek N E. Androgens and the ageing male.  Hum Reprod Update. 2002;  8 423-433
    CrossrefPubMedGoogle Scholar
  • 31 Von Eckardstein S, Nieschlag E. Therapie mit Sexualhormonen beim alternden Mann.  Dt Ärztebl. 2000;  97 A3175-A3182
    PubMedGoogle Scholar
  • 32 Fimmel S, Zouboulis C C. Influence of physiological androgen levels on wound healing and immune status in men.  Aging Male. 2005;  8 166-174
    PubMedGoogle Scholar
  • 33 Kao J S, Garg A, Mao-Qiang M, Crumrine D, Ghadially R, Feingold K R, Elias P M. Testosterone perturbs epidermal permeability barrier homeostasis.  J Invest Dermatol. 2001;  116 443-451
    CrossrefPubMedGoogle Scholar
  • 34 Gilliver S C, Wu F, Ashcroft G S. Regulatory roles of androgens in cutaneous wound healing.  Thromb Haemost. 2003;  90 978-985
    PubMedGoogle Scholar
  • 35 Gambera A, Scagliola P, Falsetti L, Sartori E, Bianchi U. Androgens, insulin-like growth factor- I (IGF-I), and carrier proteins (SHBG, IGFBP-3) in postmenopause.  Menopause. 2004;  11 159-166
    PubMedGoogle Scholar
  • 36 Ghizzani A, Razzi S, Fava A, Sartini A, Picucci K, Petraglia F. Management of sexual dysfunctions in women.  J Endocrinol Invest. 2003;  26 (Suppl 3) 137-138
    PubMedGoogle Scholar
  • 37 Buvat J. Androgen therapy with dehydroepiandrosterone.  World J Urol. 2003;  21 346-355
    CrossrefPubMedGoogle Scholar
  • 38 Hennessey J V, Chromiak J A, Della Ventura S, Reinert S E, Puhl J, Kiel D P, Rosen C J, Vandenburgh H, MacLean D B. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people.  J Am Geriatr Soc. 2001;  49 852-858
    CrossrefPubMedGoogle Scholar
  • 39 Kann P H. Growth hormone in anti-aging medicine: a critical review.  Aging Male. 2003;  6 257-263
    PubMedGoogle Scholar
  • 40 Harman S M, Blackman M R. Use of growth hormone for prevention or treatment of effects of aging.  J Gerontol A Biol Sci Med Sci. 2004;  59 652-658
    PubMedGoogle Scholar
  • 41 Savine R, Sonksen P. Growth hormone - hormone replacement for the somatopause?.  Horm Res. 2000;  53 (Suppl 3) 37-41
    CrossrefPubMedGoogle Scholar
  • 42 Mauras N, Rini A, Welch S, Sager B, Murphy S P. Synergistic effects of testosterone and growth hormone on protein metabolism and body composition in prepubertal boys.  Metabolism. 2003;  52 964-969
    CrossrefPubMedGoogle Scholar
  • 43 Prakasam G, Yeh J K, Chen M M, Castro-Magana M, Liang C T, Aloia J F. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats.  Bone. 1999;  24 491-497
    CrossrefPubMedGoogle Scholar
  • 44 Lissett C A, Shalet S M. The insulin-like growth factor-I generation test: peripheral responsiveness to growth hormone is not decreased with ageing.  Clin Endocrinol (Oxf). 2003;  58 238-245
    CrossrefPubMedGoogle Scholar
  • 45 Weber M M. Effects of growth hormone on skeletal muscle.  Horm Res. 2002;  58 (Suppl 3) 43-48
    CrossrefPubMedGoogle Scholar
  • 46 Akamatsu H, Zouboulis C C, Orfanos C E. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands.  J Invest Dermatol. 1992;  99 509-511
    CrossrefPubMedGoogle Scholar
  • 47 Deplewski D, Rosenfield R L. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation.  Endocrinology. 1999;  140 4089-4094
    CrossrefPubMedGoogle Scholar
  • 48 Zouboulis C C, Makrantonaki E. Molekulare Mechanismen der hormonellen Hautalterung.  J Dtsch Dermatol Gesellschaft. 2003;  1 (Suppl 1) S94
    PubMedGoogle Scholar
  • 49 Ruiz-Torres A, Soares de Melo Kirzner M. Ageing and longevity are related to growth hormone/ insulin-like growth factor-1 secretion.  Gerontology. 2002;  48 401-407
    CrossrefPubMedGoogle Scholar
  • 50 Lee K S, Oh K Y, Kim B C. Effects of dehydroepiandrosterone on collagen and collagenase gene expression by skin fibroblasts in culture.  J Dermatol Sci. 2000;  23 103-110
    CrossrefPubMedGoogle Scholar
  • 51 Baulieu E-E, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy M-P, Latour F, Leaud M-C, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle J-C, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.  Proc Natl Acad Sci U S A. 2000;  97 4279-4284
    CrossrefPubMedGoogle Scholar
  • 52 Percheron G, Hogrel J Y, Denot-Ledunois S, Fayet G, Forette F, Baulieu E E, Fardeau M, Marini J F. Double-blind placebo-controlled trial. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial.  Arch Intern Med. 2003;  163 720-727
    CrossrefPubMedGoogle Scholar
  • 53 Genazzani A R, Inglese S, Lombardi I, Pieri M, Bernardi F, Genazzani A D, Rovati L, Luisi M. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.  Aging Male. 2004;  7 133-143
    CrossrefPubMedGoogle Scholar
  • 54 Allolio B, Arlt W. DHEA treatment: myth or reality?.  Trends Endocrinol Metab. 2002;  13 288-294
    PubMedGoogle Scholar
  • 55 Huber J, Gruber C. Immunological and dermatological impact of progesterone.  Gynecol Endocrinol. 2001;  15 (Suppl 6) 18-21
    PubMedGoogle Scholar
  • 56 Wieser F, Hosmann J, Tschugguel W, Czerwenka K, Sedivy R, Huber J C. Progesterone increases the number of Langerhans cells in human vaginal epithelium.  Fertil Steril. 2001;  75 1234-1235
    CrossrefPubMedGoogle Scholar
  • 57 Mingjia L, Short R. How oestrogen or progesterone might change a woman’s susceptibility to HIV-1 infection.  Aust N Z J Obstet Gynaecol. 2002;  42 472-475
    CrossrefPubMedGoogle Scholar
  • 58 Fischer T W, Elsner P. The antioxidative potential of melatonin in the skin.  Curr Probl Dermatol. 2001;  29 165-174
    PubMedGoogle Scholar
  • 59 Abdel-Wahhab M A, Abdel-Galil M M, El-Lithey M. Melatonin counteracts oxidative stress in rats fed an ochratoxin A contaminated diet.  J Pineal Res. 2005;  38 130-135
    CrossrefPubMedGoogle Scholar
  • 60 Fischer T W, Greif C, Fluhr J W, Wigger-Alberti W, Elsner P. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution.  Skin Pharmacol Physiol. 2004;  17 190-194
    CrossrefPubMedGoogle Scholar
  • 61 Fischer T, Bangha E, Elsner P, Kistler G S. Suppression of UV-induced erythema by topical treatment with melatonin. Influence of the application time point.  Biol Signals Recept. 1999;  8 132-135
    CrossrefPubMedGoogle Scholar
  • 62 Zouboulis C C. The human skin as a hormone target and an endocrine gland.  Hormones. 2004;  3 9-26
    PubMedGoogle Scholar
  • 63 Cao T, Tsai S Y, O’Malley B W, Wang X J, Roop D R. The epidermis as a bioreactor: topically regulated cutaneous delivery into the circulation.  Hum Gene Ther. 2002;  13 1075-1080
    CrossrefPubMedGoogle Scholar
  • 64 Vieth R, Ladak Y, Walfish P G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D.  J Clin Endocrinol Metab. 2003;  88 185-191
    CrossrefPubMedGoogle Scholar
  • 65 Lemmey A B, Glassford J, Flick-Smith H C, Holly J M, Pell J M. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I.  J Endocrinol. 1997;  154 319-328
    CrossrefPubMedGoogle Scholar
  • 66 Zouboulis C C, Degitz K. Androgen action on human skin - from basic research to clinical significance.  Exp Dermatol. 2004;  13 (Suppl 4) 5-10
    PubMedGoogle Scholar

Prof. Dr. med. Christos C. Zouboulis

Hautklinik und Immunologisches Zentrum · Städtisches Klinikum Dessau

Auenweg 38 · 06847 Dessau

Email: christos.zouboulis@klinikum-dessau.de